BiotechTube
Orion Biotechnology

Orion Biotechnology

Basel, Switzerland· Est.
orionbiotechnology.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $18M

Overview

Orion Biotechnology is a preclinical-stage biotech company developing first-in-class GPCR-targeted therapies for obesity and metabolic diseases. Its core asset is the PROcisionX™ platform, which integrates phage display, multiplex chemical synthesis, and structure-activity analysis to generate optimized drug candidates in under six months. The company is advancing two lead candidates against the novel target GPR75 towards clinical development, led by a seasoned management team with deep pharmaceutical industry experience.

ObesityMetabolic Disorders

Technology Platform

PROcisionX™ platform: An integrated discovery platform combining streamlined phage display on native cells, multiplex chemical synthesis, structure-activity matrix analysis, and computational refinement to generate optimized peptide/small protein drug candidates for GPCR targets in under 6 months.

Funding History

2
Total raised:$18M
Series A$15M
Seed$3M

Opportunities

The massive and growing global obesity market, validated by recent blockbuster GLP-1 drugs, presents a multi-billion dollar opportunity for novel, effective therapies.
Orion's focus on the genetically validated but undrugged target GPR75 could address unmet need in patients sub-optimally served by current treatments.
Furthermore, its proprietary PROcisionX™ platform has potential application across the vast landscape of undrugged GPCRs, enabling future pipeline expansion into other therapeutic areas.

Risk Factors

High scientific risk as the novel GPR75 target is unproven in humans, and preclinical efficacy may not translate to clinical success.
Intense competition from large pharma and well-funded biotechs with advanced clinical-stage obesity compounds poses a significant commercial threat.
As a preclinical, private company, Orion faces substantial financial risk, requiring successful capital raises to fund expensive clinical development without any near-term revenue.

Competitive Landscape

Orion operates in the highly competitive obesity therapeutics arena, dominated by companies like Novo Nordisk and Eli Lilly with approved GLP-1 and multi-agonist drugs. It faces competition from numerous other biotechs developing next-generation incretin therapies, amylin analogs, and other mechanisms. Orion's differentiation lies in its novel GPR75 target and its rapid discovery platform, but it is a late preclinical entrant in a fast-moving field.

More companies in Biologics / Biosimilars →More companies in Switzerland →